Quantcast

Latest HCV Stories

2014-06-19 16:23:51

The Majority of Surveyed Primary Care Physicians Expect to Refer HCV Patients to a Specialist for Care, According to Findings from Decision Resources Group BURLINGTON, Mass., June 19, 2014 /PRNewswire/ -- Decision Resources Group finds that less than one-third of surveyed primary care physicians (PCPs) are familiar with the first-generation hepatitis C virus (HCV) protease inhibitors, Vertex's Incivek and Merck's Victrelis, despite the fact that these direct acting antivirals have been...

2014-06-18 12:29:54

Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON, Mass., June 18, 2014 /PRNewswire/ -- Decision Resources Group finds that China's market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated population, following the introduction of novel HCV therapies. Nearly a third of patients diagnosed with HCV do not receive the...

2014-06-17 04:21:28

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). Accelerated assessment, which is designated to new medicines of major public health...

2014-06-13 16:23:26

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program...

2014-06-03 12:39:28

CAMBRIDGE, Mass., June 3, 2014 /PRNewswire/ -- The National Institute of Health has awarded a Phase I Small Business Innovation Research (SBIR) grant to Daktari Diagnostics for a point-of-care hepatitis C diagnostic system. Daktari, which commercializes diagnostic platforms to meet the health care needs in Africa, Asia, and resource-limited settings worldwide, will use the grant funding to continue development of the Daktari HCV assay, which runs on the same point-of-care platform...

2014-05-29 08:29:27

SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) is pleased to announce that it has dosed the first patient in its 'first in man', Phase I/IIa clinical trial for TT-034, a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single injection. Benitec Biopharma's CEO and Managing Director, Peter French said, "The commencement of this clinical trial of TT-034 represents a landmark in the Company's...

2014-05-27 23:02:43

RxSteward, BioPlus’ cost-saving intervention program, provides significant cost savings to payers, according to data from hepatitis C patients presented at Armada’s 2014 Annual Specialty Pharmacy Summit. Altamonte Springs, FL (PRWEB) May 27, 2014 BioPlus Specialty Pharmacy (BioPlus), one of the nation’s largest specialty pharmacies specializing in hepatitis C, presented at an educational panel during Armada’s 2014 Annual Specialty Pharmacy Summit & Expo. BioPlus’...

2014-05-22 08:29:21

-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) -- Health Canada grants AbbVie's request for Priority Review MONTREAL, May 22, 2014 /CNW/ - AbbVie (NYSE: ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including...

2014-05-21 12:49:39

American Chemical Society To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way. Now scientists are solving another side of the disease's problem: identifying the millions more who have the virus but don't know it — and unwittingly pass it on. A report in the ACS journal Analytical Chemistry describes a novel, scrapbook-inspired test that does just that. Xuan Mu, Zhi Zheng...

2014-05-20 04:21:04

GENEVA, May 20, 2014 /PRNewswire/ -- The International Federation of Pharmaceutical Manufacturers and Associations [http://www.ifpma.org ] (IFPMA) has published today a new report and recommendations on Hepatitis, encouraging a comprehensive approach to fighting this silent epidemic. Titled "Towards a Sustainable, Intersectoral Approach to Viral Hepatitis [http://www.ifpma.org/fileadmin/content/Publication/2014/IFPMA_Viral_Hepatitis_May2014.pdf ] ", the report is meant to...


Latest HCV Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »
Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related